You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethyclothiazide
Accession NumberDB00232  (APRD01104)
TypeSmall Molecule
GroupsApproved
DescriptionA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
Structure
Thumb
Synonyms
Enduron
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Duretic 5mgTablet5 mgOralAbbott Laboratories, Limited1960-12-311999-08-09Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethyclothiazideTablet5 mg/1OralMylan Pharmaceuticals Inc.1982-08-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AquatensenNot Available
DureticNot Available
EnduronNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIL3H46UAC61
CAS number135-07-9
WeightAverage: 360.237
Monoisotopic: 358.956802649
Chemical FormulaC9H11Cl2N3O4S2
InChI KeyCESYKOGBSMNBPD-UHFFFAOYSA-N
InChI
InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
IUPAC Name
6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
Pharmacology
IndicationFor use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Structured Indications
PharmacodynamicsMethyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs.
Mechanism of actionMethyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 1Proteinyes
inhibitor
HumanQ13621 details
Carbonic anhydrase 1Proteinunknown
inhibitor
HumanP00915 details
Carbonic anhydrase 2Proteinunknown
inhibitor
HumanP00918 details
Carbonic anhydrase 4Proteinunknown
inhibitor
HumanP22748 details
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityAcute oral toxicity (LD50): >4000 mg/kg [Rat]. Symptoms of overdosage include electrolyte imbalance and signs of potassium deficiency such as confusion, dizziness, muscular weakness, and gastrointestinal disturbances.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methyclothiazide Action PathwayDrug actionSMP00081
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Methyclothiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Methyclothiazide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Methyclothiazide.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methyclothiazide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methyclothiazide.Withdrawn
AcetovanilloneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acetovanillone.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Methyclothiazide.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Methyclothiazide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Methyclothiazide.Experimental
AlfacalcidolMethyclothiazide may increase the hypercalcemic activities of Alfacalcidol.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methyclothiazide.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Methyclothiazide.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methyclothiazide.Experimental, Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Methyclothiazide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Methyclothiazide.Investigational
AnisodamineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Methyclothiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Methyclothiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Methyclothiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Atenolol.Approved
Atracurium besylateThe serum concentration of Methyclothiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Methyclothiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methyclothiazide.Investigational
BalsalazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Methyclothiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Methyclothiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Methyclothiazide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
BenactyzineThe serum concentration of Methyclothiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bendroflumethiazide.Approved
BenoxaprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Methyclothiazide can be increased when it is combined with Benzatropine.Approved
BepridilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methyclothiazide.Approved
Betulinic AcidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Betulinic Acid.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Methyclothiazide.Experimental, Illicit, Withdrawn
BiperidenThe serum concentration of Methyclothiazide can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Brimonidine.Approved
BromfenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bromocriptine.Approved, Investigational
BucillamineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Methyclothiazide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methyclothiazide.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methyclothiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methyclothiazide.Approved, Illicit, Vet Approved
CalcidiolMethyclothiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolMethyclothiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalcitriolMethyclothiazide may increase the hypercalcemic activities of Calcitriol.Approved, Nutraceutical
CalciumMethyclothiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateMethyclothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium carbonateMethyclothiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.Approved
Calcium ChlorideMethyclothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium citrateMethyclothiazide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.Approved
Calcium glubionateMethyclothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateMethyclothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateMethyclothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Candesartan.Approved
CandoxatrilMethyclothiazide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methyclothiazide.Illicit, Vet Approved
CarprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Methyclothiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorthalidone.Approved
CholecalciferolMethyclothiazide may increase the hypercalcemic activities of Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methyclothiazide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cilnidipine.Approved
CitalopramCitalopram may increase the hyponatremic activities of Methyclothiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Methyclothiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Methyclothiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Methyclothiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clonidine.Approved
ClonixinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methyclothiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Methyclothiazide.Approved
CurcuminThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Methyclothiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclophosphamide.Approved, Investigational
D-LimoneneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Methyclothiazide.Investigational
DarifenacinThe serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.Approved, Investigational
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Methyclothiazide.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Methyclothiazide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Methyclothiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Methyclothiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Methyclothiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Methyclothiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Methyclothiazide.Vet Approved
DexetimideThe serum concentration of Methyclothiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Methyclothiazide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methyclothiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methyclothiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methyclothiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Methyclothiazide.Approved
DiflunisalThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Methyclothiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Methyclothiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methyclothiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methyclothiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methyclothiazide.Experimental, Illicit
DihydrotachysterolMethyclothiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methyclothiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Methyclothiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Methyclothiazide.Approved
DofetilideMethyclothiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.Approved
DoxercalciferolMethyclothiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methyclothiazide.Investigational
DroxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methyclothiazide.Approved
DuloxetineMethyclothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ebselen.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Enalapril.Approved, Vet Approved
EnalaprilatMethyclothiazide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Methyclothiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Methyclothiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Methyclothiazide.Approved
ErgocalciferolMethyclothiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Methyclothiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyclothiazide.Approved
EstroneEstrone may increase the hypokalemic activities of Methyclothiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Methyclothiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.Approved
EtanerceptThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
EthopropazineThe serum concentration of Methyclothiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methyclothiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Methyclothiazide.Approved
EtoricoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methyclothiazide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Methyclothiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methyclothiazide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Fimasartan.Approved
FloctafenineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Methyclothiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
FlunixinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flunixin.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Methyclothiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Methyclothiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Methyclothiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Methyclothiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Methyclothiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Methyclothiazide.Approved
FlurbiprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Methyclothiazide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Methyclothiazide.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Methyclothiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Furosemide.Approved, Vet Approved
Gallamine TriethiodideThe serum concentration of Methyclothiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methyclothiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methyclothiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methyclothiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methyclothiazide.Approved
GlycopyrroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methyclothiazide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Methyclothiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methyclothiazide.Approved, Illicit
HexamethoniumThe serum concentration of Methyclothiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
HigenamineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with HMPL-004.Investigational
HomatropineThe serum concentration of Methyclothiazide can be increased when it is combined with Homatropine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide.Approved, Illicit
HyoscyamineThe serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Icatibant.Approved
IloprostThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Methyclothiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Methyclothiazide.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indapamide.Approved
IndomethacinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methyclothiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methyclothiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methyclothiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methyclothiazide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methyclothiazide.Approved
Ipratropium bromideThe serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isocarboxazid.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Methyclothiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Methyclothiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isradipine.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Methyclothiazide.Investigational
IvabradineMethyclothiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methyclothiazide.Approved
KetoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lacidipine.Approved
LeflunomideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levobupivacaine.Approved
LevodopaMethyclothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methyclothiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Methyclothiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methyclothiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Methyclothiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methyclothiazide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumMethyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methyclothiazide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.Approved
MannitolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Masoprocol.Approved
ME-609ME-609 may increase the hypokalemic activities of Methyclothiazide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Methyclothiazide.Approved
Mefenamic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Methyclothiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methyclothiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methyclothiazide.Approved, Illicit
MethanthelineThe serum concentration of Methyclothiazide can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Methyclothiazide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metoprolol.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methyclothiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Methyclothiazide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Minoxidil.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Moexipril.Approved
MometasoneMometasone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.Approved
N-butylscopolammonium bromideThe serum concentration of Methyclothiazide can be increased when it is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methyclothiazide.Approved
NaproxenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Methyclothiazide.Investigational
NCX 4016The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Methyclothiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Methyclothiazide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nifedipine.Approved
Niflumic AcidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Niflumic Acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Methyclothiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methyclothiazide.Approved, Illicit
NVA237The serum concentration of Methyclothiazide can be increased when it is combined with NVA237.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Obinutuzumab.Approved
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Methyclothiazide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Methyclothiazide.Approved
OlopatadineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatMethyclothiazide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methyclothiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Methyclothiazide.Approved
OrgoteinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.Approved
OuabainThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oxcarbazepine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oxprenolol.Approved
OxybutyninThe serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methyclothiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methyclothiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Methyclothiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Paclitaxel.Approved, Vet Approved
PancuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
ParecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parecoxib.Approved
ParicalcitolMethyclothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Methyclothiazide.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pentolinium.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methyclothiazide.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Methyclothiazide.Approved, Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pipamperone.Approved
PipecuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Methyclothiazide.Approved
PirenzepineThe serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Methyclothiazide.Investigational
PiroxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Methyclothiazide.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prazosin.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Methyclothiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Methyclothiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Methyclothiazide.Approved
ProcyclidineThe serum concentration of Methyclothiazide can be increased when it is combined with Procyclidine.Approved
PropacetamolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Methyclothiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Methyclothiazide can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propranolol.Approved, Investigational
PTC299The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Methyclothiazide can be increased when it is combined with Quinidine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Methyclothiazide.Approved
RasagilineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methyclothiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
RescinnamineMethyclothiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methyclothiazide.Approved
ResveratrolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Methyclothiazide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Riociguat.Approved
RisperidoneMethyclothiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Methyclothiazide.Approved
RofecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Methyclothiazide.Approved
SalsalateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide.Approved
ScopolamineThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Seratrodast.Approved, Investigational
SertralineSertraline may increase the hyponatremic activities of Methyclothiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sevoflurane.Approved, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium Nitrite.Approved
SolifenacinThe serum concentration of Methyclothiazide can be increased when it is combined with Solifenacin.Approved
SotalolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.Approved
SpiraprilMethyclothiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.Approved
SRT501The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
TamsulosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methyclothiazide.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Telmisartan.Approved, Investigational
TemocaprilMethyclothiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Methyclothiazide.Approved
TeriflunomideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Methyclothiazide.Investigational
ThiopentalThiopental may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TimololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Timolol.Approved
TinoridineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Methyclothiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Methyclothiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.Approved
TolterodineThe serum concentration of Methyclothiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateMethyclothiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.Approved
ToremifeneMethyclothiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methyclothiazide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Trandolapril.Approved
TranilastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.Approved
TrihexyphenidylThe serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimethaphanThe serum concentration of Methyclothiazide can be increased when it is combined with Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Trisalicylate-choline.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methyclothiazide.Withdrawn
TropicamideThe serum concentration of Methyclothiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Methyclothiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Methyclothiazide can be increased when it is combined with Tubocurarine.Approved
UmeclidiniumThe serum concentration of Methyclothiazide can be increased when it is combined with Umeclidinium.Approved
ValdecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide.Approved, Investigational
VecuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Methyclothiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Methyclothiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methyclothiazide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methyclothiazide.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Methyclothiazide.Withdrawn
ZomepiracThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC03AA08C03AB08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9834
Blood Brain Barrier-0.6866
Caco-2 permeable-0.6992
P-glycoprotein substrateSubstrate0.5317
P-glycoprotein inhibitor INon-inhibitor0.8518
P-glycoprotein inhibitor IINon-inhibitor0.8888
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.631
CYP450 2D6 substrateNon-substrate0.8261
CYP450 3A4 substrateNon-substrate0.532
CYP450 1A2 substrateNon-inhibitor0.6883
CYP450 2C9 inhibitorNon-inhibitor0.6493
CYP450 2D6 inhibitorNon-inhibitor0.858
CYP450 2C19 inhibitorNon-inhibitor0.808
CYP450 3A4 inhibitorInhibitor0.5094
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7345
Ames testNon AMES toxic0.8905
CarcinogenicityNon-carcinogens0.82
BiodegradationNot ready biodegradable0.9971
Rat acute toxicity1.9853 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9384
hERG inhibition (predictor II)Non-inhibitor0.9318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Abbott laboratories pharmaceutical products div
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Methyclothiazide powder11.32USD g
Enduron 5 mg tablet0.77USD tablet
Methyclothiazide 5 mg tablet0.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point225 °CPhysProp
water solubility11.2 mg/LNot Available
logP1.42HANSCH,C ET AL. (1995)
pKa9.4MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.824 mg/mLALOGPS
logP0.93ALOGPS
logP0.53ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.28 m3·mol-1ChemAxon
Polarizability31.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Couloigner V, Loiseau A, Sterkers O, Amiel C, Ferrary E: Effect of locally applied drugs on the endolymphatic sac potential. Laryngoscope. 1998 Apr;108(4 Pt 1):592-8. [PubMed:9546276 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Meyerson LR, Nesta D: [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells. Biochem Pharmacol. 1991 Mar 15-Apr 1;41(6-7):995-1000. [PubMed:1901209 ]
  2. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23